{
    "name": "nafarelin",
    "comment": "Rx",
    "other_names": [
        "Synarel"
    ],
    "classes": [
        "Gonadotropin Releasing Hormone Agonists"
    ],
    "source": "https://reference.medscape.com/drug/synarel-nafarelin-342759",
    "pregnancy": {
        "common": [
            "Pregnancy Category: X",
            "Lactation: Excretion in milk unknown, contraindicated"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Lactation: Excretion in milk unknown, contraindicated"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Pregnancy, hypersensitivity, lactation, undiagnosed abnormal vaginal bleeding"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Goal in adult females is to suppress menstruation; max treatment period 6 mth",
                "May cause increase in bone turnover & decrease in bone mineral content",
                "Ovarian cysts may develop within first 2 months of therapy and occur more commonly in women with polycystic ovarian disease",
                "Cases of pituitary apoplexy reported",
                "Use caution in patients with risk factors for decreased bone mineral density",
                "Irregular or incomplete daily doses may result in stimulation of the pituitary-gonadal axis; counsel caregivers to assure full compliance",
                "During first month of treatment, may initially expect some signs of puberty, e.g., vaginal bleeding or breast enlargement, may occur; such changes should resolve soon after first month; if such resolution does not occur within first two months of treatment, this may be due to lack of compliance or presence of gonadotropin independent sexual precocity; if both possibilities excluded, the dose omay be increased to 1800 mcg/day administered as 600 mcg tid",
                "Patients with intercurrent rhinitis should consult their physician for use of topical nasal decongestant; if use of topical nasal decongestant required during treatment decongestant should not be used until at least 2 hr after administering therapy; sneezing during or immediately after administering therapy should be avoided, if possible, since may impair drug absorption",
                "Convulsions reported in patients receiving GnRH agonists; reports with GnRH agonists have included patients with a history of seizures, epilepsy, cerebrovascular disorders, central nervous system anomalies or tumors, and patients on concomitant medications that have been associated with convulsions such as bupropion and SSRIs; convulsions also reported in patients in the absence of any of the conditions listed",
                "Psychiatric events reported in patients taking GnRH agonists; postmarketing reports with this class of drugs include symptoms of emotional lability, such as crying, irritability, impatience, anger, and aggression; monitor for development or worsening of psychiatric symptoms during treatment",
                "Depression may occur or worsen during treatment with GnRH agonists; carefully observe women for depression, especially those with a history of depression, and consider whether risks of continuing therapy outweigh benefits; women with new or worsening depression should be referred to a mental health professional, as appropriate; inform patients that depression may occur or worsen during treatment with GnRH agonists, especially in patients with history of depression; advise patients to immediately report thoughts and behaviors of concern to healthcare providers",
                "Pseudotumor cerebri (idiopathic intracranial hypertension) reported in pediatric patients receiving GnRH agonists, including leuprolide acetate; monitor patients for signs and symptoms of pseudotumor cerebri, including headache, papilledema, blurred vision, diplopia, loss of vision, pain behind the eye or pain with eye movement, tinnitus, dizziness, and nausea; inform patients and caregivers that reports of pseudotumor cerebri have occurred"
            ],
            "specific": []
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Acne",
            "percent": "10"
        },
        {
            "name": "Breast enlargement",
            "percent": "8"
        },
        {
            "name": "Vaginal bleeding",
            "percent": "8"
        },
        {
            "name": "Seborrhea",
            "percent": "3"
        },
        {
            "name": "Emotional lability",
            "percent": "6"
        },
        {
            "name": "Vaginal discharge",
            "percent": "3"
        },
        {
            "name": "Rhinitis",
            "percent": "5"
        },
        {
            "name": "Body odor",
            "percent": "4"
        },
        {
            "name": "Increase in pubic hair",
            "percent": "5"
        },
        {
            "name": "Arthralgia",
            "percent": null
        },
        {
            "name": "Breast engorgement",
            "percent": null
        },
        {
            "name": "Chloasma",
            "percent": null
        },
        {
            "name": "Maculopapular rash",
            "percent": null
        },
        {
            "name": "Paresthesia",
            "percent": null
        },
        {
            "name": "Weakness",
            "percent": null
        },
        {
            "name": "Palpitation",
            "percent": null
        },
        {
            "name": "Eye pain",
            "percent": null
        },
        {
            "name": "Liver injury",
            "percent": null
        },
        {
            "name": "Pituitary apoplexy",
            "percent": null
        },
        {
            "name": "Seizures",
            "percent": null
        },
        {
            "name": "Pituitary gland changes",
            "percent": null
        },
        {
            "name": "Liver injury",
            "percent": null
        },
        {
            "name": "rare",
            "percent": null
        },
        {
            "name": "Ovarian hyperstimulation syndrome",
            "percent": null
        },
        {
            "name": "Psychiatric Disorders",
            "percent": null
        },
        {
            "name": "Emotional lability",
            "percent": null
        },
        {
            "name": "including crying",
            "percent": null
        },
        {
            "name": "irritability",
            "percent": null
        },
        {
            "name": "impatience",
            "percent": null
        },
        {
            "name": "anger",
            "percent": null
        },
        {
            "name": "and aggression",
            "percent": null
        },
        {
            "name": "mood swings",
            "percent": null
        },
        {
            "name": "depression",
            "percent": null
        },
        {
            "name": "including rare reports of suicidal ideation and attempt",
            "percent": null
        },
        {
            "name": "in children treated for central precocious puberty",
            "percent": null
        },
        {
            "name": "Pseudotumor cerebri",
            "percent": null
        },
        {
            "name": "idiopathic intracranial hypertension",
            "percent": null
        }
    ]
}